Status:
UNKNOWN
Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis
Lead Sponsor:
McGill University
Collaborating Sponsors:
Innodem Neurosciences
Conditions:
Clinically Isolated Syndrome
Relapsing Remitting Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate seve...
Eligibility Criteria
Inclusion
- For all participants
- Able to provide informed consent
- Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted)
- For patients only
- Confirmed diagnosis of CIS with abnormal MRI or RRMS
- Neurological condition is medically stable during the study visit
Exclusion
- For all participants:
- Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
- Aged above 65 or less than 18 years of age.
- Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (Strabismus, cranial nerve palsy, stroke-causing hemianopsia).
- Diagnosis of macular edema or other pre-existing ocular conditions that would prevent from performing the eye movement assessments.
- For healthy controls only:
- Evidence or history of significant neurological disorder (Multiple Sclerosis, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Dementia)
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05277740
Start Date
September 1 2022
End Date
July 1 2024
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada, H3A 2B4